AbbVie broadens its telisotuzumab conjugate push
A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
The month ahead: September’s upcoming events
It’s a new term for biotech and its investors.
AbbVie gets a cMet niche
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
Regeneron’s Met bet falls short
The Met x Met ADC REGN5093-M114 has been discontinued, but a Met x Met bispecific antibody remains.
The month ahead: December’s upcoming events
Party season approaches; but first, conferences.
